Despite its impressive performance in 2020 and 2021, it's no secret that (NYSE: PFE) is in the process of reinventing itself. Without much of the windfall from its coronavirus products propping up the top line, it may be years until revenue can top its recent peak.

But that just means the company has an incentive to make big plays and take big risks to delight its shareholders. On that front, here's my prediction for what its next major move will be.

At the moment, Pfizer's grand plan is to lay the groundwork for its growth through 2030 and beyond. As part of that plan, it expects to add $20 billion in revenue from sales of new medicines produced with its own research and development (R&D) capabilities, and $25 billion from acquisitions of other biopharmas and their most promising pharmaceutical assets.

Continue reading

Source Fool.com